Old Well Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Old Well Partners’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-23,487	Closed	-$279K	–	40
2021 Q1	$279K	Buy	+23,487	New	+$270K	0.14%	27
2020 Q4	–	Sell	-17,575	Closed	-$130K	–	44
2020 Q3	$130K	Buy	+17,575	New	+$114K	0.12%	28

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Old Well Partners's ALDX Position: Q2 2021 in Review

Old Well Partners sold out of Aldeyra Therapeutics (ALDX) in Q2 2021, closing a stake of 23,487 shares — an estimated $279K sold.

Old Well Partners first reported a position in ALDX in Q3 2020 and held it in 2 quarters. The position peaked at $279K in Q1 2021. 136 funds tracked by Wall St. Rank hold ALDX as of Q2 2021.

Old Well Partners reported no remaining Aldeyra Therapeutics position as of Q2 2021 after selling out during the quarter.
Old Well Partners sold 23,487 Aldeyra Therapeutics shares in Q2 2021, an estimated $279K.
Old Well Partners first reported a position in Aldeyra Therapeutics in Q3 2020 and held it in 2 quarters.
Old Well Partners's Aldeyra Therapeutics position peaked at $279K in Q1 2021.
136 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2021.

Based on Old Well Partners's 13F filing for Q2 2021, filed 16 Aug 2021.